After Treatment, Patients With Germ Cell Cancer Face High Toxicity, Death Risk

Share this content:
Patients with germ cell cancer who survive after more than one line of treatment face a significantly increased risk of late toxicity and death.
Patients with germ cell cancer who survive after more than one line of treatment face a significantly increased risk of late toxicity and death.

Patients with germ cell cancer (GCC) who survive after more than one line of treatment for disseminated disease face a significantly increased risk of late toxicity and death from other causes, according to a recent study published online ahead of print in the Journal of Clinical Oncology.

Gedske Daugaard, MD, DMSc, of the Copenhagen University Hospital in Denmark and fellow researchers looked at 268 patients who received more than one line of treatment for disseminated GCC from the Danish Testicular Cancer database, assessing for late toxicity and mortality through national registers.

Prognostic factors for risk of relapse and death were also compared with International prognostic Factors Study Group (IPFSG) classifications.

“The purpose of this study was to evaluate late toxicity and survival in an unselected cohort of patients who experienced relapse after receiving first-line treatment for disseminated disease,” the authors noted. Among the observed patients, 136 had died from GCC.

Compared to patients who were treated with only orchiectomy, the remaining 132 patients in the observed population faced an increased risk for a second cancer, major cardiovascular disease, pulmonary disease, gastrointestinal disease, renal impairment, neurologic disorder, and death as a result of other causes.

RELATED: For Older Patients with Lung Cancer, Limited Resection Not Equivalent to Lobectomy

The IPFSG classifications were largely found to be confirmed in the observed patients, with increasing age as a possible new prognostic factor for treatment failure after second-line treatment.

The authors concluded that patients with GCC who survive after more than one line of treatment “should be candidates for life-long follow-up” as a result of toxicity and death risk from other causes than GCC.

Reference

  1. Lauritsen J, Kier MGG, Mortensen MS, et al. Germ cell cancer and multiple relapses: toxicity and survival. J Clin Oncol. 2015. [epub ahead of print]. doi: 10.1200/JCO.2014.60.1310.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters